Posted on January 20, 20261/20/26
Navigating A New Era: Reflections on Canada’s Enhanced CDA-AMC Reimbursement Review Process
Posted on January 14, 20261/14/26
The Combination Crossfire: Is Your Brand Strategy Strong Enough to Align Payers, Prescribers, and Patients?
Posted on January 14, 20261/14/26
NAVLIN Daily 2025 Round-Up: The Pricing and Policy Trends Redefining Market Access
Posted on January 5, 20261/5/26
A New Marketing Mandate in Community Oncology
Posted on December 17, 202512/17/25
The Enablement Helix: An Evolving Framework for Market Success in Oncology
Posted on December 10, 202512/10/25
Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis
Posted on December 3, 202512/3/25
New Direct-to-Employer Access Model Provides Options for Employers to Improve Access to Weight Loss Medications
Posted on October 16, 202510/16/25
Let’s Be DIRECT: We Have An Access and Affordability Problem to Solve
Posted on October 9, 202510/9/25
Navigating the New HTA Landscape: Pamela Vo on Strategic Evidence Planning
Posted on October 1, 202510/1/25